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( ABSTRACT 
Objective: Using a self-administered questionnaire, the objectives of this study were : 
(1) to identify the predictors that discriminate between the patients who consider 
returning to antihypertensive therapy and those who indicate that they will not return to 
drug therapy; (2) to compare the predictors of returning to antihypertensive drug 
therapy in a North American population (United States, and Canada) with a European 
(France, Germany, and Italy) population. 
Design: Cross-sectional study. 
Data Collection: An existing dataset was obtained from Bristol Myers Squibb (BMS), 
New Jersey. BMS recruited patients with a diagnosis of hypertension from five different 
countries (USA, Canada, France, Germany, and Italy) (n=731). Trained interviewers 
administered the questionnaire in one-on-one interview sessions at a research facility, 
interviewer's home, or patient's home. 
Methodology: Required variables were extracted from the dataset usmg SAS 
(Statistical Analysis System). The patients who said that they were already taking their 
antihypertensive medication as directed were deleted from the study. Therefore the final 
sample of 439 patients was used for the analyses. Independent variables were divided 
into four groups and logistic regression analyses were carried out separately for each 
sets of variables. The significant variables from each set of variables were identified and 
combined to develop a final logistic regression model. Finally, the study sample was 
divided into North American population and European population. A final logistic 
regression model was developed separately for these two populations. 
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( Results: The number of physician visits for blood pressure problems, number of 
medication additions to the ones that patients were already taking for their blood 
pressure, patients' satisfaction towards the assistance they received from their health 
care provider in managing high blood pressure, and patients' satisfaction with the 
medications that were available to use to manage their blood pressure were identified as 
significant predictors in the final model. The European population showed two 
significant predictors that include number of physician visits for blood pressure 
problems and patients' satisfaction with the medications that were available to use in 
manage their blood pressure. However, North American population showed only one 
significant predictor that is number of medication additions to the ones that patients 
were already taking to manage their blood pressure. No interaction terms were found to 
be significant. The model worked best for the set of psychological variables. 
Conclusion: The treatment of hypertension remains a difficult task. A frequent reason 
is poor adherence to the drug regimen. The results indicate that an increase in the 
number of physician visits for blood pressure problems may improve the odds of 
reinitiating drug therapy. The increase in number of physician visits for blood pressure 
problems may help patients to consider reinitiating antihypertensive drug therapy 
The difference of predictors in North American and European population necessitates 
further investigation in separate geographical areas. The identification of predictors in 
each location may help in customizing the compliance improvement strategy. 
lll 
I Continued research in this area is vital because once the predictors of adherence to drug 
therapy are identified, effective interventions can be implemented to improve it. The 
interventions could be followed by its assessment. The feedback from assessment will 
help in modifying the interventions. 
IV 
( ACKNOWLEDGEMENT 
Together, each achieves more. This project has been a great teamwork. There have been 
many people who contributed to finish my thesis successfully. Although, I would like to 
mention all of them, I will only name few who made a big difference. 
First of all, I would like to thank Dr. Larrat for being my major professor. He was very 
understanding and always made me comfortable. He taught me how to fish rather than 
giving me a fish. His constant encouragement and support has helped me to sharpen my 
research skills. I can't do without thanking Dr. Willey. I am indebted to her for giving 
me a research project in my area of interest. She always took time out of her busy 
schedule and shared her wisdom so that I move further in this project. 
I would like to express my gratitude to Dr. Campbell and Dr. Jarrett for always being 
there for me when I needed them. They have been a great resource for this assignment. 
They always brought best out of me and made me feel better every time I met them. I 
want to thank Dr. Lipson, Dr. Breheny, and Dr. Andrade for sharing their knowledge 
and help me understand many areas of U.S health care system. Also, thanks to Kathy 
and Ann for their constant support. 
I would also like to acknowledge some people who have helped me behind the scene. I 
cannot thank enough to Neelam and Amogh who helped me do some things that made a 
big difference to this project. Thanks to Swapnil, Uma, Alkesh, and Vrushali for 
v 
( showing me light at the end of tunnel in many situations and keep me moving. 
I can't forget to thank my parents and sisters because of whom I came to the University 
of Rhode Island. Finally, I would like to thank Sheetal for being a tremendous source of 
inspiration and love for me. 
Vl 
ABSTRACTS 
ACKNOWLEDGEMENT 
TABLE OF CONTENTS 
LIST OF TABLES 
INTRODUCTION 
METHODOLOGY 
RESULTS 
DISCUSSION 
CONCLUSION 
TABLES 
REFERENCES 
APPENDIX 
BIBLIOGRAPHY 
TABLE OF CONTENTS 
vu 
Page 
11 
v 
vu 
Vlll 
1 
9 
20 
23 
28 
30 
52 
57 
102 
( LIST OFT ABLES 
Table Page 
1. Characteristics of the study population that have discontinued 31 
antihypertensive drug therapy (N=439). 
2. Logistic regression model for patients' current feeling about 32 
reinitiating drug therapy. Regression coefficients, standard error, 
and chi-square for demographic characteristics. 
3. Logistic regression model for patients ' current feeling about 33 
reinitiating drug therapy. Regression coefficient, standard error, 
and chi-square for demographic characteristics including 
marital status. 
4. Logistic regression model for patients' current feeling about 34 
reinitiating drug therapy. Regression coefficient, standard error, 
and chi-square for demographic characteristics including 
relatives' health status. 
5. Logistic regression model for patients' current feeling about 35 
reinitiating drug therapy. Regression coefficient, standard error, 
and chi-square for demographic characteristics including 
interactions. 
6. Logistic regression model for patients ' current feeling about 36 
reinitiating drug therapy. Regression coefficient, standard error, 
and chi-square for disease related variables. 
7. Logistic regression model for patients' current feeling about 37 
reinitiating drug therapy. Regression coefficient, standard error, 
and chi-square for disease related variables. 
8. Logistic regression model for patients' current feeling about 38 
reinitiating drug therapy. Regression coefficient, standard error, 
and chi-square for psychological variables. 
9. Logistic regression model for patients' current feeling about 39 
reinitiating drug therapy. Regression coefficient, standard error, 
and chi-square for psychological variables including interactions. 
10. Logistic regression model for patients ' current feeling about 40 
reinitiating drug therapy. Regression coefficient, standard error, 
and chi-square for medication related variables. 
Vlll 
( 11. Logistic regression model for patients' current feeling about reinitiating drug therapy. Regression coefficient, standard error, 
and chi-square for medication related variables without the 
variable for current medication being taken. 
41 
12. Final logistic regression model without interactions for patients ' 42 
current feeling about reinitiating drug therapy. Regression 
coefficients, standard error, and chi-square for the final set 
of variables. 
13. Final logistic regression model for patients' current feeling 43 
about reinitiating drug therapy. Regression coefficients, standard 
error, and chi-square for the final set of variables including 
interactions. 
14. Final logistic regression model for patients' current feeling 44 
about reinitiating drug therapy. Regression coefficients, standard 
error, and chi-square for the final set of variables belonging to 
North American population. 
15. Final logistic regression model for patients' current feeling 45 
about reinitiating drug therapy. Regression coefficients, standard 
error, and chi-square for the final set of variables belonging to 
European population. 
16. Adjusted odds ratios and confidence intervals for demographic 46 
variables. 
17. Adjusted odds ratios and confidence intervals for disease related 47 
variables. 
18. Adjusted odds ratios and confidence intervals for psychological 48 
variables. 
19. Adjusted odds ratios and confidence intervals for medication related 49 
variables. 
20. Adjusted odds ratios and confidence intervals for the final set of 50 
variables. 
21 . Adjusted odds ratios and confidence intervals for the final set of 51 
variables in North American population. 
22. Adjusted odds ratios and confidence intervals for the final set of 52 
variables in European population. 
lX 
( 
INTRODUCTION 
A. Importance of compliance in antihypertensive drug therapy 
Hypertension is one of the most prevalent cardiovascular diseases in the United States, 
afflicting about 50 million people. [1] The results of a survey conducted in the United 
States, Canada, the United Kingdom and western European countries indicate that no 
more than 30% of patients maintain target blood pressure levels while on medication. 
[2] Another survey recently conducted in the US indicated that only 27 % of 
hypertensive patients had their systolic and diastolic blood pressure below 140mm and 
90mm of Hg, respectively. [3] Although this can't be attributed to a single factor, in one 
study treatment failure is attributed by 70% of respondent physicians to a problem with 
adherence to therapy. [ 4] According to a study by a team of researchers from the 
University of Lausanne, Switzerland, as many as half of "failures" of treatment to lower 
blood pressure to normal levels may be due to noncompliance by patients in taking 
antihypertensive drugs as prescribed. Another study conducted on a random sample of 
243 hypertensive patients indicated that 30-46% of the patients were noncompliant with 
their antihypertensive drug regimens. [5] 
It is estimated that only 50-74% of hypertensive patients are currently receiving drug 
therapy and that the drug controls the condition in only 50% of patients receiving 
therapy. [6] Outpatient costs for treating hypertension were $13.9 billion in 1997. Half 
of this amount was spent on antihypertensive medication despite the low overall rates of 
use. [7] Although drug therapy has proven to be an effective form of control for high 
blood pressure, poor adherence to therapy drastically decreases its effectiveness. [8] It is 
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estimated that 30-50% of hypertensive patients withdraw from their prescribed regimen 
within one year of diagnosis and, of the remainder; nearly 33% administer insufficient 
medication to facilitate an adequate reduction in blood pressure. [9, 1 O] Untreated 
hypertension carries a significant risk of cerebrovascular accidents (CV A), heart disease 
and renal disease. Each year, 100,000 people suffer their first CV A, with a total of 
63,407 British deaths (12% of national mortality) being attributed to CVA in 1989. [11] 
In a study conducted by Michel Brunier, MD, and colleagues, there was a strong 
association between lapses in compliance and increases in blood pressure. They also 
reported a significant inverse correlation between measured compliance and ambulatory 
diastolic blood pressure. [2] 
The Healthy People 2000 report set a goal of increasing the proportion of hypertensive 
Americans whose condition is well controlled to at least 50%. [12] A study conducted 
by Mark Monane et al. indicates that antihypertensive compliance averaged 49%, and 
only 23% of the cohort had good compliance levels of 80% or higher. [13] The 
consequences of noncompliance with antihypertensive drug therapy include poor blood 
pressure [14], hospital admission [9] and nursing home placement. [15] It is necessary 
for patients to tale more than 80% of their antihypertensive drugs to maintain adequate 
blood pressure control. [ 16] The review of previous studies suggests that 
noncompliance with prescribed drug regimens is a widespread problem in the medical 
field. [17] 
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( Because of noncompliance, many patients require extra care that results in a cost of 
billions of dollars to health care each year. [18,19] The results from a prospective study 
notes that poor compliance is probably the major reason for the low impact of 
antihypertensive drugs in the real world (' effectiveness') as compared to those enrolled 
in drug studies ('efficacy') . [20] A withdrawal syndrome caused by abrupt 
discontinuation of P-adrenoceptor blocking agents may include tachycardia, malaise, 
tremor and anxiety. [21] Cases of exacerbation of acute angina, myocardial infarction 
and sudden death have been reported in patients with ischernic heart disease who 
discontinued p blockers. [22] A dangerous, sometimes fatal increase in blood pressure 
may occur as a result of clonidine withdrawal. [23] Discontinuation of centrally acting 
antihypertensive drugs such as methyldopa and clonidine may also result into 
withdrawal syndromes. [24] In general, the abrupt cessation of antihypertensive 
medication is usually without immediate consequences. However, it maybe associated 
with symptoms and signs of enhanced sympathetic activity, severe hypertension, 
morbid ischemic cardiovascular events or death. [25] A retrospective analysis of 1.2 
million patients concluded that low rates of continuation with a newly prescribed 
antihypertensive drug exist regardless of which drug is prescribed. [26] This conclusion 
generates several questions about the possible reasons of such a high rate of 
discontinuation of treatment from newly prescribed antihypertensive drugs. 
B. Determinants of compliance 
Researchers have determined many factors associated with compliance. Some of these 
factors include the patient's knowledge concerning medical regimens, the seriousness of 
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( the disease, and the consequences of untreated disease. [27,28]. The other factors 
include a patient's belief about the effectiveness of the medication [29], family/social 
support [30], cost of medications [19], number of medications being taken by the 
patient. [31] 
A retrospective cohort of 4068 elderly outpatients newly starting antihypertensive 
therapy from 1982 through 1988 was utilized to measure compliance and related 
demographic factors. It indicated that younger age and black race were associated with 
lower levels of drug utilization. [ 11] A cross-sectional retrospective study of ambulatory 
population was conducted at the University of Rhode Island to find the factors 
associated with compliance problems. The study indicated that a patient's level of 
understanding of both medication instructions and the drug therapy is associated with 
compliance problems. The other factors associated include length of time since last 
physician visit, length of time on medication, total number of medications and number 
of drug allergies. The class of medication taken was also found to be a significant 
predictor of excess risk. The age and sex appeared to have little association. [ 18] The 
literature review indicates that angiotensin-converting-enzyme (ACE) inhibitors have 
had the highest compliance rates, followed by calcium-channel blockers, ~-blockers and 
diuretics. [32-35] 
The health belief model predicts that the oldest patients, with greater severity of 
disease, are more motivated to comply. [10] In addition, very old patients are more 
likely to have caregivers at home to assist with medication use. A pilot study was 
conducted in which a questionnaire was devised and administered to a random sample 
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( of 243 hypertensive patients of the adult ambulatory care clinic to understand the 
incidence of noncompliance and contributing factor. It indicated that that employment, 
use of home remedies, age, experience of side effects, level of concern with missed 
doses and cost are associated with noncompliance. [ 42] 
Previous research indicates that noncompliance is a problem. However, there is 
inconsistency in the reasons for noncompliance. [5] Continued research in this area is 
essential because once the predictors of noncompliance have been found, effective 
interventions can be implemented to improve compliance. 
C. Assessment of compliance 
There is no ideal method for measuring drug compliance. [36,37] The methods that are 
commonly used to measure compliance include follow-up, outcome of therapy, 
prescription refills, direct questioning, pill counts, drug assays, and electronic 
medication monitoring. 
Follow-up appointments: The physician may get some information on his/her patient 
compliance by looking at the way he/she keeps the appointment. In many countries, the 
patient is allowed to choose his doctors. Therefore, patient who does not show up any 
more may still be compliant and seeking the treatment from another doctor. 
Outcome of therapy: Whether patient shows a good control of blood pressure or not is 
used as an indicator of compliance. However, this is a weak indicator. Any medication 
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r taken regularly is not effective in approximately half of hypertensive patients. (38] A 
patient may be compliant and unresponsive to multiple therapies. 
Prescription refills: The compliance can be evaluated by monitoring the prescription. 
This technique is especially useful in a community of hypertensive patient, for example, 
those belonging to a given medical care system. It can hardly be done in the individual 
patient if the prescriber and dispenser of the medication are different. (38] 
Direct questioning: This method is commonly used because it is relatively simple and 
inexpensive. In a clinical setting, the easiest way to evaluate compliance is to interview 
the patient about his habits of taking the prescribed treatment. Previous studies have 
shown that about 15-50 % of noncompliant patients can be identified by interview. 
Direct questioning is of little help in individual patients. However, when considering a 
group of hypertensive patients, there exist some link between blood pressure 
normalization rate and the reported degree of compliance. (39] 
Pill count: It has been traditionally used to monitor compliance in antihypertensive drug 
trials. However, this method tends to overestimate compliance. This is mainly because 
patients may discard tablets before returning the container to their doctor. (36] There is 
some evidence that compliance assessed by pill count must be 80% or more on order to 
obtain significant blood pressure reduction. [ 40] 
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I Drug assays: This method utilizes plasma and unne concentration to measure 
compliance. The accuracy of this method partly depends on half-life of the drug. It is 
very inconvenient and can be expensive. The patient may be reluctant to give blood 
sample. 
Medication Event Monitoring System (MEMS): It utilizes a computer chip in the cap of 
the medicinal bottle. Information is recorded each time the bottle is open. It allows 
calculation of the compliance rate, prescribed frequency, and prescribed interval. 
D. Hypotheses 
For the purpose of this study, we had proposed the following hypotheses: 
1) Demographic characteristics such as age, race, gender, education level, medical 
insurance coverage, income and employment affect reinitiating antihypertensive 
drug therapy after discontinuation. 
2) Psychological factors such as mood status, patient' perception about general 
health status and patient satisfaction affect reinitiating antihypertensive drug 
therapy after discontinuation. 
3) Disease related factors such as physical functioning, # of hospitalizations, # of 
ER visits, #of physician visits, #of Nurse/Physician Assistant/Nurse 
Practitioner visits affect reinitiating antihypertensive drug therapy after 
discontinuation. 
4) The prescribing patterns of physician and medication type affect reinitiating 
antihypertensive drug therapy after discontinuation. 
7 
I 5) The predictors ofreturning to antihypertensive drug therapy for North American 
population (United States and Canada) differ from European population 
(Germany, France and Italy). 
8 
( METHODOLOGY 
Study sample 
An existing data set was obtained from Bristol Myers Squibb (BMS). The objectives of 
this study were: (1) to identify the predictors that discriminate between the patients who 
consider returning to antihypertensive therapy and those who indicate that they will not 
return to drug therapy; (2) to compare the predictors of returning to antihypertensive 
drug therapy in a North American population (United States, and Canada) with a 
European (France, Germany, and Italy) population. The data were recorded such that 
subjects cannot be identified directly or through identifiers linked to the subjects. BMS 
recruited the patients with a diagnosis of hypertension from five different countries (US, 
Canada, France, Germany and Italy) (n=731 ). Patients were identified primarily through 
physicians, pharmacists, patient networks and newspaper advertisements. Professional 
recruiters contacted each patient to determine eligibility. All patients were required to 
have been prescribed an antihypertensive agent from 3-18 months prior to the interview, 
and to have never been diagnosed or treated for angina, ischemic heart disease, 
arrhythmia, arteriosclerosis, cardiac bypass surgery, angioplasty, myocardial infarction 
or stroke. Individuals who were prescribed medication, but had never taken it, or 
individuals who had discontinued their medication were over-recruited to ensure an 
adequate distribution of those who were non-compliant. Only those patients diagnosed 
as being hypertensive after 1991 were considered for this study. Therefore, the data on 
718 patients were used for the purpose of this study. The dependent variable was 
dichotomized to reflect whether a study participant was considering reinitiating their 
medication or not. We were only interested in the patients that had stopped taking their 
9 
( medications. The patients who said that they were completely taking medications as 
directed were deleted from the study. Therefore, the final sample of 439 patients was 
left for the analyses. 
Data collection 
Trained interviewers explained that the purpose of the study was to understand attitudes 
about having high blood pressure, and that all the answers would be kept confidential, 
and that no one, including the patient's physician, would be able to identify their 
responses. The questionnaire was administered in a one-on-one interview session at a 
research facility, interviewer's home, or patient's home. The interviewer reviewed 
instructions for each section of the questionnaire and was able to answer questions as 
the patient completed the forms. 
Measures and variables assessed 
The questionnaire included measures of stage change for adherence, pros and cons of 
adherence, processes of change for adherence, temptation to skip medication, 
demographic and clinical variables, and self-reported adherence with medication for 
hypertension 
The following independent variables were extracted from the database. 
Demographic characteristics: 
Age, race, gender, education level, medication payment type, income, employment were 
considered. 
Physical functioning: 
The scale was taken from the SHORT-FORM-36 HEALTH SURVEY developed by 
Rand Corporation and John E. Ware (1990). It was designed as a generic indicator of 
10 
health status for use in population surveys and evaluative studies of health policy. The 
SF-36 survey includes one multiple-item scale measuring each of eight general health 
concepts: physical functioning (PF), role limitations due to physical health problems 
(RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social 
functioning (SF), role limitations due to emotional problems (RE), and mental health 
(MH). The questions were measured on a six point likert scale from none of the time 
(score of one) to all of the time (score of 6). The questions for physical functioning 
include: 
a. Did you have problem in performing vigorous activities such as running, lifting 
heavy objects, and strenuous sports? 
b. Did you have problem in performing moderate activities such as moving a table, 
vacuuming, and bowling? 
c. Did you have problem in lifting or carrying groceries? 
d. Did you have problem in climbing several flights of stairs? 
e. Did you have problem in climbing one flight of stairs? 
f. Did you have problem in bending, kneeling or stooping.? 
g. Did you have problem in walking more than a mile? 
h. Did you have problem in walking several blocks? 
1. Did you have problem in walking one block? 
J. Did you have problem in bathing or dressing yourself? 
Likert's method for surnmated ratings scale was used to score each SF-36 scale. The 
score for few items were either recalibrated or reversed so that higher scores always 
indicate better health states. These scores for item responses were summed. A missing 
11 
scale score was assigned if more than half of the items in each scale were missing. If 
one-half or fewer items in each scale were missing, mean of the non-missing items was 
substituted for the missing items. Finally all the scales were linearly transformed to a 0 
to 100 scale, with 100 indicating the most favorable health scale, 0 the least favorable, 
and scores in between representing the percent of the total possible score achieved. The 
following formula was used for transformation: 
Transformed score= (actual - lowest possible score)* 100 
Possible raw score range 
Patient visits: 
Number of hypertension related hospitalizations, number of ER (emergency room) 
visits for blood pressure problems, number of physician visits for problems, and number 
of nurse/physician assistant/nurse practitioner visits for problems were considered. 
Mood status: 
The scale was taken from the SHORT-FORM-36 HEALTH SURVEY developed by 
Rand Corporation and John E. Ware (1990). The questions for mental health scale 
include: 
a. Have you been a nervous person? 
b. Have you felt so down in the dumps that nothing could cheer you up? 
c. Have you felt calm and peaceful? 
d. Have you felt downhearted and blue? 
e. Have you been a happy person? 
The detailed procedure is described above in physical functioning scale. 
General health status: 
Excellent to poor scale was considered. 
12 
Patient satisfaction: 
Patient satisfaction towards health care provider, self-management, degree of control, 
medications, and other services were considered. 
Prescribing patterns of physicians: 
Number of dosage changes, number of medication additions, number of medication 
deletions, and number of medication switches were considered. 
Medication type: 
Medication/medications prescribed for the first time for the high blood pressure, current 
medication/medications being used for high blood pressure were considered. 
Dependent variable: 
Patients ' current feeling about reinitiating drug therapy as directed was treated as a 
dependent variable. This variable was dichotomized based upon the following 
responses: 
• No, right now I am not considering taking my high blood pressure medication as 
directed. 
• Yes, right now I am considering or planning to start taking my high blood 
pressure medication as directed. 
Data analysis 
Statistical analysis: 
The data were analyzed using the Statistical Analysis System (SAS) Version 8.0 on the 
IBM compatible computer at the University of Rhode Island. Proc LOGISTIC was 
utilized to perform the analysis for all logistic regression models. All independent 
variables were divided into 4 separate categories that include demographic variables, 
13 
disease related variables, psychological variables, and medication related variables. This 
strategy was used to avoid too many numbers of variables in a single model. PROC 
LOGISTIC was utilized for these primary models. Important independent variables 
were identified from the model using Chi-square test. The important variables were 
inserted as interaction terms in these models. The analysis was repeated to identify 
significant interactions. The variables with significant regression coefficient were 
identified from each model. These variables were combined to develop a final model. 
This stepwise approach helped us to reduce the number of independent variables in the 
final model. Finally, participants were divided into two groups that included North 
American population (USA, and Canada), and European population (France, Germany, 
and Italy) The final logistic regression model was carried out separately for these two 
groups. 
The variables were coded as following. 
Demographic characteristics: 
Age: continuous 
Race: 
White - 1 
Nonwhite - 2 
Gender: categorical 
Male - 1 
Female - 2 
Education level: categorical 
< High school degree - 1 
14 
( >= High school degree - 2 
Medical payment type: categorical 
Not reimbursed - 1 
Reimbursed - 2 
Income: categorical 
<30k - l 
>=30k - 2 
Employment: categorical 
Full time/part time - 1 
Unemployed/homemaker/student/retired - 2 
Disease related characteristics: 
Physical functioning scale: continuous 
Number of hypertension related patient visits: continuous 
Number of ER visits for blood pressure problems: continuous 
Number of physician visits for problems: continuous 
Number of nurse/physician assistant/nurse practitioner visits for problems: 
continuous 
Psychological characteristics: 
Mental health scale: continuous 
General health status: ordinal 
Poor - I 
Fair - 2 
Good-3 
15 
( Very good - 4 
Excellent - 5 
Patients' satisfaction towards health care: ordinal 
Very dissatisfied to Very satisfied - 1 to 10 
Patients' satisfaction towards self-management: ordinal 
Very dissatisfied to Very satisfied - 1 to 10 
Patients' satisfaction towards degree of blood pressure control: ordinal 
Very dissatisfied to Very satisfied - 1 to 10 
Patients' satisfaction towards medications: ordinal 
Very dissatisfied to Very satisfied - 1 to 10 
Patients' satisfaction towards other services: ordinal 
Very dissatisfied to Very satisfied - 1 to 10 
Medication related variables: 
Number of dosage changes: continuous 
Number of medication additions: continuous 
Number of medication deletions: continuous 
Number of medication switches: continuous 
Medication/medications prescribed for the first time for high blood pressure: 
categorical 
Diuretics - 1 
Nondiuretics - 0 
Medication/medications currently being used for high blood pressure: categorical 
Diuretics - 1 
16 
( Nondiuretics - 0 
Logistics regression model for demographic characteristics: 
1. Patients' current feeling about reinitiating drug therapy= age + education level 
+ employment + income + medical payment type + race + gender. 
2. Patients' current feeling about reinitiating drug therapy= age + education level 
+ employment + income + medical payment type + race + gender + marital 
status. 
3. Patients' current feeling about reinitiating drug therapy= age + education level 
+ employment + income + medical payment type + race + gender + relatives 
with health problems. 
4. Patients' current feeling about reinitiating drug therapy = age + education level 
+employment+ income+ medical payment type+ race+ gender+ race* gender 
+ medical payment type*race. 
Logistics regression model for disease related characteristics: 
1. Patients' current feeling about reinitiating drug therapy = physical functioning 
scale + number of hypertension related hospitalizations + number of ER visits 
for problems + number of nurse/physician assistant/nurse practitioner visit for 
problems. 
2. Patients' current feeling about reinitiating drug therapy = physical functioning 
scale + number of hypertension related hospitalizations + number of ER visits 
for problems + number of nurse/physician assistant/nurse practitioner visit for 
problems +physical functioning scale*number of physician visits for problems. 
17 
Logistics regression model for psychological characteristics: 
1. Patients' current feeling about reinitiating drug therapy = mental health scale + 
general health status + patients ' satisfaction towards health care provider + 
patients' satisfaction towards self-management+ patients ' satisfaction towards 
degree of control + patients' satisfaction towards medication + patients ' 
satisfaction towards other services. 
2. Patients' current feeling about reinitiating drug therapy = mental health scale + 
general health status + patients' satisfaction towards health care provider + 
patients ' satisfaction towards self-management+ patients ' satisfaction towards 
degree of control + patients' satisfaction towards medication + patients ' 
satisfaction towards other services + patients' satisfaction towards health care 
provider*patients' satisfaction towards self-management + patients ' satisfaction 
towards self-management*patients' satisfaction towards medications + patients ' 
satisfaction towards health care provider*patients ' satisfaction towards 
medications. 
Logistics regression model for medication related characteristics: 
1. Patients' current feeling about reinitiating drug therapy = medication prescribed 
for the first time for high blood pressure + current medication being used for 
high blood pressure + number of dosage changes + number of medication 
additions + number of medication deletions + number of medication switches. 
2. Patients ' current feeling about reinitiating drug therapy = medication prescribed 
for the first time for high blood pressure + number of dosage changes + number 
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of medication additions + number of medication deletions + number of 
medication switches. 
Final logistic regression models: 
1. Patients' current feeling about reinitiating drug therapy = race + number of 
physician visits for high blood pressure problems + patients' satisfaction 
towards health care provider+ patients' satisfaction towards high blood pressure 
medication+ number of high blood pressure medication deletions. 
Final logistic regression model for North American population: 
2. Patients' current feeling about reinitiating drug therapy = race + number of 
physician visits for high blood pressure problems + patients' satisfaction 
towards health care provider+ patients' satisfaction towards high blood pressure 
medication+ number of high blood pressure medication deletions. 
Final logistic regression model for North American population: 
3. Patients' current feeling about reinitiating drug therapy = race + number of 
physician visits for high blood pressure problems + patients' satisfaction 
towards health care provider+ patients' satisfaction towards high blood pressure 
medication+ number of high blood pressure medication deletions. 
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RESULTS 
A total of 731 patients were enrolled in the study. Among all, 439 patients met our 
study criteria.14% of the patients were less than 40 years of age. More than half (55%) 
of the participants were male. Most of the patients were white (95%) and only 3.4 % 
black. Most of the participants (81 %) had a total household annual income of $50000 
and above. More than half (61 %) of the study population lived in Europe (France, 
Germany, and Italy), and rest in North America (USA, and Canada). 66% of the 
participants had at least a high school degree. Half of the study population was 
employed (full time/part time), while 36 % were retired.70% of the population were 
government/work reimbursed. Only 12% were without any reimbursement. 
Relationship between patients' willingness to reinitiate drug therapy and 
demographic characteristics (Table 2-5, and Table 15): 
The likelihood ratio test shows that all logistic regression models for demographic 
variables are significant. Medical payment type (Chi-square = 6.1608, p = 0.0131), and 
race (Chi-square = 5.7563, p = 0.0164) showed a significant effect on reinitiating of 
antihypertensive therapy at 0.05 significance level. Both the variables reported 
significant adjusted odds ratios (Table 15). The interaction terms (race*gender, and 
medical payment type*race) were not significant (Table 5). The exploratory variable; 
marital status (Table 3) was not significant. Relatives' health status was found to be 
significant (Chi-square = 6.7026, p = 0.0096). This variable had 159 missing 
observations. Therefore, it was not considered in the final logistic regression model. 
Relationship between patients' willingness to reinitiate drug therapy and disease 
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( related characteristics (Table 6-7 and Table 16): 
Physician health scale (Chi-square= 8.0292, p = 0.0046) and number of physician visits 
for problems (Chi-square= 7.7352, p = 0.0054) had a significant effect at 0.05 level of 
significance. Both the variables did not show significant odds ratio (Table 16). 
Relationship between patients' willingness to reinitiate drug therapy and 
psychological characteristics (Table 8-9 and Table 17): 
The overall models were significant (chi-square = 70.9671. p < 0.0001). Patients' 
satisfactions towards their health acre provider (chi-square= 14.8340, p = 0.0001), self 
management (chi-square 9.0428, p = 0.0026), and medications (chi-square= 23.7400, p 
< 0.0001) were found to have significant effect at 0.05 level of significance. No 
interaction terms were significant (Table 9). 
Relationship between patients' willingness to reinitiate drug therapy and 
medication related characteristics (Table 10-11 and Table 18): 
My original logistic regression model for medication related characteristics (chi-square 
= 9.9055, p = 0.1287, Table 10) were not significant. However, the second model 
without a variable for current medication being taken (Table 11) was significant (chi-
square = 35.8503, p < 0.0001). The number of medication addition (chi-square = 
8.4624, p = 0.0036) was found to be significantly associated with the dependent 
variable at 0.05 significance level. The odds of reinitiating drug therapy increased by 
1.77 units with one unit increase in number of medication additions (OR 2.77, 95% CI 
1.394 to 5.5020, Table 18). 
Relationship between patients' willingness to reinitiate drug therapy and final set 
of independent variables (Table 12 and Table 19): 
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The number of physician visits for blood pressure problems, patients' satisfaction with 
the assistance from health care provider in managing their high blood pressure, patients' 
satisfaction with the medication they were taking for high blood pressure, and number 
of medication additions (Table 12) showed a significant effect on the dependent 
variable. Only number of medication additions reported a significant odds ratio (OR 
1.746, 95% CI 1.097 to 2.777, Table 19). 
Relationship between patients' willingness to reinitiate drug therapy and final set 
of independent variables for North American Population (Table 13 and Table 20): 
Only number of medication additions to the ones that patients were already taking for 
high blood pressure (Table 13) showed a significant effect on the dependent variable. It 
reported a significant odds ratio (OR 3.683, 95% CI 1.313, 10.331). The odds of 
reinitiating antihypertensive drug therapy increased by 2.683 units with one unit 
increase in the number of medications for high blood pressure. 
Relationship between patients' willingness to reinitiate drug therapy and final set 
of independent variables for European Population (Table 15 and Table 22): 
The model was found to be significant (chi-square 63.625, p < 0.0001). The number of 
physician visits for problems, patients' satisfaction with the medications that are 
available to use for managing their high blood pressure had a significant effect on the 
dependent variable (Table 15). None of these two variables reported a significant odds 
ratio (Table 21 ). 
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DISCUSSION 
This study examined four sets of variables that were hypothesized to be predictors of 
willingness to reinitiate antihypertensive drug therapy. The factors examined included 
demographic characteristic, disease related characteristics, psychological characteristics, 
and medication related characteristics. 
Demographic characteristics: 
All the demographic characteristics that include race,age, gender, education level, 
medical payment type, income, and employment status could not predict patients' 
willingness to reinitiate drug therapy. This is consistent with most of the studies. 
However, other studies indicate that age, gender, employment, medical payment type 
are associated with medication compliance in antihypertensive patients. [10,18,41,42] 
There seem to be inconsistency in different studies. This necessitates further 
investigation of demographic characteristics as the predictors of compliance. 
Disease related characteristics: 
Among all the number of physician visits for blood pressure problems was found to be 
the only significant predictor. One study reported that good compliance in 
antihypertensive therapy is significantly associated with multiple physician visits. This 
consistent finding may signify the importance of patients' education by physician. More 
number of physician visits for blood pressure problem may have added opportunity for 
education of patients to reinitiate antihypertensive drug therapy. Physical health scale, 
number of hypertension related hospitalizations, number of ER visits and number of 
nurse/physician assistant/nurse practitioner visits for problems were not significantly 
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( associated with the adherence to drug therapy. Previous study reports that number of 
hospitalizations was not significantly associated with compliance. [34] 
The variables such as limitation in moderate activities, limitation in climbing flight 
upstairs were replaced with a single variable called physical health scale for making the 
model simple and interpretable. 
Psychological characteristics: 
Patients' satisfaction with the assistance they receive from their health care provider in 
managing their high blood pressure and patients' satisfaction with the medications that 
were available to use for high blood pressure were significantly associated with 
reinitiating of antihypertensive drug therapy. This is a significant finding since previous 
studies have not reported information on these types of characteristics. This may 
suggest that increase in the assistance from health care provider in managing high blood 
pressure will increase the odds of patients reinitiating antihypertensive drug therapy. It 
indicates the importance of health care provider's role in medication compliance. As 
expected, increased satisfaction with the medications that are available to use in 
managing high blood pressure increased the odds of reinitiating antihypertensive drug 
therapy. 
Although patients' satisfaction with their ability to help themselves (self-management) 
in managing their blood pressure was a significant predictor in the primary model, it 
was not considered in the final model. This is because we thought that this variable may 
obscure the relationship of other variables with patients willingness to reinitiate drug 
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therapy (dependent variable). To avoid large a number of variables, mood status 
variables were replaced with one variable called mental health scale. 
Medication related characteristics: 
Surprisingly, the number of medication additions to the ones that patients were already 
taking for their high blood pressure was positively associated with patients' willingness 
to reinitiate drug therapy. This is not consistent with previous studies. Two studies show 
the inverse association of number of medications with drug compliance. [18,34] 
Another study shows the number of medications to be an insignificant predictor. [ 42] 
Frequency of dosage changes, medication prescribed for the first time, number of 
medication deletions, and number of medication switches were not found to be 
significant predictors. Our literature review does not reveal studies of these 
characteristics on compliance of antihypertensive medications. Likelihood ratio test 
indicates that the set of psychological variables worked the best (Chi-square = 51.1384, 
p<0.0001). The number of medication additions was found to be the best predictor (OR 
= 1.746, 95% CI 1.097,2.777). 
Final models for North America and European population: 
The number of medication additions was found to be an important predictor in North 
American population. However, in European population number of physician visits for 
blood pressure problems and patients' satisfaction with the medications that are 
available to use in managing their high blood pressure were found to be significant 
predictors. Factors affecting compliance may vary across populations. [ 43] No study 
reports the comparison of predictors in different population using the same compliance 
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evaluation method. This study shows the difference between the predictors in the North 
American and European populations. Generally, the differences in the results of 
compliance studies may be because of the differences in definitions of compliance and 
health belief. [ 43] However the former does not apply in this study since same methods 
of compliance evaluation have been used in both the population. This suggests that the 
differences in health belief between North American and European population may be 
the reason for the differences in the predictors. This indicates the need to further define 
factors that might affect the compliance in a population before implementing 
interventions to improve compliance. This customized approach will also avoid misuse 
of the resources for interventions to improve compliance. 
Interactions: 
We attempted to identify different interaction terms in this study. The selection of 
interaction terms was based upon theory and/or significance of the variable in 
preliminary analyses. 
Limitations: 
Self-reported data: people may be inaccurate in reporting their behavior. There may be 
multiple influences on them in terms of their ability and desire to provide a valid 
response. These factors may include clarity of questions, setting, memory, literacy, 
mood status etc. 
Measurement: There seems to be no "gold standard" or satisfactory way to measure 
compliance. However the questionnaire has been designed to cover every aspect of 
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patient's mood, disease status, coping, demographics etc. that can help in identifying the 
predictors of noncompliance. 
Generalizabiltiy: Factors such as mood status or the clinical condition of a particular 
patient limit the generalizability of the results to the entire hypertensive population. The 
study population was not randomly selected. This also puts limitation on extrapolating 
the results for the entire population. 
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CONCLUSION 
The primary objective of this study was to identify the predictors that discriminate 
between the patients who consider returning to antihypertensive drug therapy and those 
who indicate that they will not return to drug therapy. The secondary objective was to 
examine whether there were any differences in the predictors of returning to 
antihypertensive drug therapy in North American population and European populations. 
Separate logistic regression models were run for four sets of variables. The predictors 
identified from each model were combined to run a final logistic regression model. The 
demographic variables such as race, age, education level, employment, income, gender, 
and medical payment type had little effect on patients' willingness to reinitiating drug 
therapy. 
The number of physician visits for blood pressure problems was associated with the 
reinitiating of the drug therapy. Surprisingly, number of medication additions was 
positively associated with the patients' adherence to drug therapy. Patients ' satisfaction 
with the assistance from health care provider in managing high blood pressure and 
patients' satisfaction with the medication that they were already taking in managing 
their blood pressure were also positively associated. 
Finally, a logistic regression model was run separately for North American population 
and European population. The number of medication additions to the ones that patients 
were already taking for their high blood pressure was the only significant predictor in 
North American population. However, in the European population we noted that 
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number of physician visits for blood pressure problems and patients' satisfaction with 
the medications that they were taking to manage their high blood pressure were 
significant predictors. 
The treatment of hypertension remams a difficult task. A frequent reason is poor 
adherence to the drug regimen. The results indicate that an increase in the number of 
physician visits for blood pressure problems may improve the odds of reinitiating drug 
therapy. The increase in number of physician visits for blood pressure problems may 
help patients to consider reinitiating antihypertensive drug therapy 
The difference of predictors in North American and European population necessitates 
f 
further investigation in separate geographical areas. The identification of predictors in 
\ 
each location may help in customizing the compliance improvement strategy. 
Continued research in this area is vital because once the predictors of adherence to drug 
therapy are identified, effective interventions can be implemented to improve it. The 
interventions could be followed by its assessment. The feedback from assessment will 
help in modifying the interventions. 
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( Table 1. Characteristics of the study population that have discontinued 
antihypertensive drug therapy (N=439) 
Dem~a.£_hics nl_%l 
Age 
0-25 10 (2.2) 
26-40 51 (11.7) 
41-64 280 (63 .8) 
65 and above 98 (22 .3) 
Gender 
Women 242 (45) 
Men 197 (55) 
Race 
White 417 (95) 
Black 15 (3.4) 
Hispanic 5(1.1) 
Asian 2 (0.5) 
Income* 
<20k 104 (26.8) 
20k to <30k 97 (25 .0) 
30k to <50k 111 (28.6) 
50k to <75k 53 (13 .7) 
75k to <lOOk 17 (4.3) 
>= lOOk 5 ( 1.29) 
Country 
USA 126 (28 .7) 
Canada 40 (9.2) 
France 92 (20.9) 
Germany 106 (24.2) 
Italy 75 (17) 
Education 
Elementary High School 55 (12 .5) 
Some High School 92 (21) 
High School degree 91 (20.8) 
BUSffECH School degree 61 (14) 
Some School 47 (10.7) 
College degree 36 (8 .2) 
Some Grad School 24 (5.5) 
Grad School degree 32 (7.3) 
Employment Status 
Full-time 164 (38) 
Part-time 50(11.6) 
Unemployed 21 (4.9) 
Homemaker 39 (9) 
Student 1 (0.2) 
Retired 157 (36.3) 
Medical Payment Type 
Not reimbursed 50 (12) 
Government reimbursed 185 (43) 
Work insurance reimbursed 116 (27) 
Self insurance reimbursed 79 i_l~ 
*: 52 missing records 
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( Table 2: Logistic regression model for patients' current feeling about 
reinitiating drug therapy. Regression coefficients, standard error, and 
chi-square for demographic characteristicst . 
Variable Estimate Standard Chi-square p 
error 
In terce_l!.t -3 .9822 1.1952 11.1008 0.0009* 
Age 0.0115 0.0090 1.6083 0.2047 
Education 0.2500 0.2068 1.4608 0.2268 
Level 
Employment -0.0032 0.2441 0.0002 0.9895 
Income -0.1641 0.2025 0.6561 0.4179 
Medical 0.7839 0.3225 5.9075 0.0151* 
Payment 
Type 
Race 1.2523 0.5117 5.9905 0.0144* 
Gender 0.3377 0.1980 2.9074 0.0882 
* Significant at small a probability (0.05 or less) 
t Chi-square= 16.6039, P = 0.0201 *(Likelihood Ratio Test) 
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( Table 3: Logistic regression model for patients' current feeling about 
reinitiating drug therapy. Regression coefficient, standard error, and 
chi-square for demographic characteristics including marital statust. 
Variable Estimate Standard Chi-Square 
Error 
Intercept -4.0875 1.1999 11.6038 
A_g_e 0.0120 0.0090 1.7493 
Education 0.2237 0.2091 1.1447 
level 
Em..E_lo_yment -0.0122 0.2444 0.0025 
Income -0.1044 0.2133 0.2395 
Medical 0.8037 0.3238 6.1608 
..E_a_yment type 
Race 1.2248 0.5105 5.7563 
Gender 0.3133 0.1999 2.4575 
Marital 0.2011 0.2247 0.8006 
Status 
* Significant at small a probability (0.05 or less) 
t Chi-square = 17.4059, P = 0.0261 *(Likelihood Ratio Test) 
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p 
0.0007 
* 
0.1860 
0.2847 
0.9601 
0.6245 
0.0131 
* 
0.0164 
* 
0.1170 
0.3709 
( Table 4: Logistic regression model for patients' current feeling about 
reinitiating drug therapy. Regression coefficient, standard error, and 
chi-square for demographic characteristics including relatives' health statust. 
Variable Estimate Standard Chi-square p 
error 
Interc~t -3.0196 1.4560 4.3011 0.0381 * 
A__g_e 0.0103 0.0112 0.8371 0.3602 
Education 0.0519 0.2620 0.0393 0.8429 
level 
Emj!_lo_yment -0.1543 0.3023 0.2606 0.6097 
Income 0.1270 0.2605 0.2375 0.6260 
Medical 1.0649 0.4281 6.1876 0.0129* 
_p_~ment _!yp_e 
Race 1.2927 0.5718 5.1110 0.0238* 
Gender 0.1585 0.2540 0.3894 0.5326 
Relatives' -0.6683 0.2581 6.7026 0.0096* 
health status 
* Significant at small a probability (0.05 or less) 
t Chi-square= 16.3184, P = 0.0380 (Likelihood Ratio Test) 
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I Table 5: Logistic regression model for patients' current feeling about 
reinitiating drug therapy. Regression coefficient, standard error, and 
chi-square for demographic characteristics including interactionst. 
Variable Estimate Standard Chi-square 
error 
Interce_l!_t -1.2337 3.0778 0.1607 
A_g_e 0.0107 0.0091 1.3881 
Education 0.2632 0.2078 1.6045 
level 
Employment 0.0100 0.2446 0.0017 
level 
Income -0.1769 0.2048 0.7460 
Medical -0.1891 1.2963 0.0213 
_l!_a_yment !Y£_e 
Race -1.2750 2.6770 0.2269 
Gender -0.3992 1.1459 0.1214 
Race*Gender 0.7073 1.0920 0.4196 
Medical 0.8434 1.1564 0.5968 
payment 
.!YE_e*Race 
* Significant at small a probability (0.05 or less) 
t Chi-square= 17.6068, P = 0.0400* (Likelihood Ratio Test) 
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p 
0.6885 
0.2387 
0.2053 
0.9672 
0.3878 
0.8840 
0.6339 
0.7275 
0.5172 
0.4398 
Table 6: Table 6: Logistic regression model for patients' current feeling 
about reinitiating drug therapy. Regression coefficient, standard error, 
and chi-square for disease related variablest. 
Variable Estimate Standard Chi-square p 
error 
Interc~t 1.5071 0.5809 6.7321 0.0095* 
Physical health -0.0332 0.0117 8.0292 0.0046* 
scale 
Number of 0.0376 0.4370 0.0074 0.9315 
hypertension 
related 
hos~italizations 
Number of ER 0.0297 0.4078 0.0053 0.9419 
visits for blood 
pressure 
~roblems 
Number of 0.1084 0.0390 7.7351 0.0054* 
physicians' 
visits for 
_problems 
Number of -0.0033 0.0520 0.0041 0.9488 
nurse/physician 
assistant/nurse 
practitioner 
visits for 
~roblems 
* Significant at small a probability (0.05 or less) 
t Chi-square= 23.0518, P = 0.0030* (Likelihood Ratio Test) 
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Table 7: Table 6: Logistic regression model for patients' current feeling 
about reinitiating drug therapy. Regression coefficient, standard error, 
and chi-square for disease related variablest. 
Variable Estimate Standard Chi-square p 
error 
Interce_p_t 1.5189 0.6461 5.5271 0.0187* 
Physical health -0.0335 0.0132 6.4495 0.0111 * 
scale __{Pscalti 
Number of 0.0416 0.4462 0.0087 0.9257 
hypertension 
related 
hos_p_italizations 
Number of ER 0.0301 0.4077 0.0054 0.9412 
visits for blood 
pressure 
_p_roblems 
Number of 0.0997 0.2102 0.2253 0.6350 
physicians' 
visits for 
problems 
_{_Ph_y~ 
Number of -0.0031 0.0521 0.0037 0.9513 
nurse/physician 
assistant/nurse 
practitioner 
visits for 
_p_roblems 
Pscale*Ph_ys 0.0001 0.0044 0.0018 0.9666 
* Significant at small a probability (0.05 or less) 
t Chi-square= 23.0536, P = 0.008* (Likelihood Ratio Test) 
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I Table 8: Logistic regression model for patients' current feeling about 
reinitiating drug therapy. Regression coefficient, standard error, and 
chi-square for psychological variablest. 
Variable Estimate Standard Chi-square 
error 
Interce_l)_t -0.4049 0.6397 0.4007 
Mental health -0.0038 0.0120 0.1050 
scale 
General -0.0720 0.1479 0.2371 
health status 
Patients' 0.2187 0.0568 14.8340 
satisfaction 
towards 
health care 
_l)_rovider 
Patients' -0.2010 0.0668 9.0428 
satisfaction 
towards self-
man~ement 
Patients' -0.0687 0.0745 0.8512 
satisfaction 
towards 
degree of 
control 
Patients' 0.2512 0.0516 23.7400 
satisfaction 
towards 
medications 
Patients' -0.0759 0.0515 2.1725 
satisfaction 
towards other 
services 
* Significant at small a probability (0.05 or less) 
t Chi-square = 70.9671 , P = 0.0001 *(Likelihood Ratio Test) 
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p 
0.5267 
0.7459 
0.6163 
0.0001 * 
0.0026* 
0.3562 
<0.0001 
* 
0.1405 
Table 9: Logistic regression model for patients' current feeling about 
reinitiating drug therapy. Regression coefficient, standard error, and 
chi-square for psychological variables including interactionst. 
Variable Estimate Standard Chi-square 
error 
In terce_.l!_t -0.8450 0.1583 0.5321 
Mental health -0.0030 0.0120 0.0623 
scale 
General -0.0611 0.1502 0.1653 
health status 
Patients' 0.2896 0.1437 4.0645 
satisfaction 
towards 
health care 
_.1!._rovider _(Al 
Patients' 0.0475 0.1541 0.0950 
satisfaction 
towards self-
management 
ill 
Patients' -0.1052 0.0776 1.8384 
satisfaction 
towards 
degree of 
control_iCl 
Patients' 0.0818 0.1589 0.2650 
satisfaction 
towards 
medications 
_(Dl 
Patients' -0.0719 0.0521 1.9022 
satisfaction 
towards other 
services _(El 
A*B -0.0345 0.0183 3.5393 
B*D -0.0004 0.0173 0.0008 
A*D 0.0264 0.0190 1.9287 
* Significant at small a probability (0.05 or less) 
t Chi-square= 75.3419, P = 0.0010* (Likelihood Ratio Test) 
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p 
0.4657 
0.8029 
0.6843 
0.0438* 
0.7579 
0.1751 
0.6067 
1.1678 
0.0599 
0.9775 
0.1649 
Table 10: Logistic regression model for patients' current feeling about 
reinitiating drug therapy. Regression coefficient, standard error, and 
chi-square for medication related variablest. 
Variable Estimate Standard Chi-square p 
error 
Interce_.E._t 0.1808 0.5756 0.0986 0.7535 
Medication -0.3463 0.6217 0.3102 0.5775 
prescribed 
for the first 
time 
Medication 0.6241 0.7374 0.7164 0.3973 
currently 
bein_g_ taken 
Frequency of 0.0636 0.2817 0.0509 0.8215 
dosage 
chan_g_es 
Number of 1.2192 0.5139 5.6294 0.0177 
medication * 
additions 
Number of 0.4893 0.4942 0.9803 0.3221 
medication 
deletions 
Number of 0.1365 0.4308 0.1004 0.7514 
medication 
switches 
* Significant at small a probability (0.05 or Jess) 
t Chi-square= 9.9055, P = 0.1287 (Likelihood Ratio Test) 
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Table 11: Logistic regression model for patients' current feeling about 
reinitiating drug therapy. Regression coefficient, standard error, and 
chi-square for medication related variables without the variable for current 
medication being takent. 
Variable Estimate Standard Chi-square p 
error 
Interce_.l!_t -0.1106 0.1412 0.6137 0.4334 
Medication -0.2704 0.2626 1.0606 0.3031 
prescribed 
for the first 
time 
Frequency of 0.2972 0.1525 3.7963 0.0514 
dosage 
chan_g_es 
Number of 1.0187 0.3502 8.4624 0.0036 
medication * 
additions 
Number of -0.2329 0.2063 2.4653 0.1164 
medication 
deletions 
Number of 0.2800 0.2407 1.3532 0.2449 
medication 
switches 
* Significant at small a probability (0.05 or less) 
t Chi-square= 35.8503, P < 0.0001 *(Likelihood Ratio Test) 
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Table 12: Final logistic regression model without interactions for patients' 
current feeling about reinitiating drug therapy. Regression coefficients, 
standard error, and chi-square for the final set of variablest. 
Variable Estimate Standard Chi-square p 
error 
In tercel!_t -2.8071 0.6576 18.2236 <0.0001 * 
Race 0.9663 0.5156 3.5129 0.0609 
Number of 0.1119 0.0437 6.5656 0.0104* 
physician 
visits for 
l!_roblems 
Patients' 0.1061 0.0505 4.4088 0.0358* 
satisfaction 
towards 
health care 
l!_rovider 
Patients' 0.1320 0.0443 8.8831 0.0029* 
satisfaction 
towards 
medications 
Number of 0.5570 0.2369 5.5276 0.0187* 
medication 
additions 
* Significant at small a probability (0.05 or Jess) 
t Chi-square= 51.1384, P < 0.0001 *(Likelihood Ratio Test) 
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Table 13: Final logistic regression model for patients' current feeling 
about reinitiating drug therapy. Regression coefficients, standard error, 
and chi-square for the final set of variables belonging to North American 
populationt. 
Variable Estimate Standard Chi-square p 
error 
Interce_1>_t -2.8452 0.8282 11.8017 0.0006* 
Race 0.8351 0.5526 2.2844 0.1307 
Number of -0.0271 0.0666 0.1653 0.6843 
physician 
visits for 
_p_roblems 
Patients' 0.1456 0.0775 3.5303 0.0603 
satisfaction 
towards 
health care 
_p_rovider 
Patients' 0.1137 0.0706 2.5972 0.1071 
satisfaction 
towards 
medications 
Number of 1.3039 0.5262 6.1407 0.0132* 
medication 
additions 
* Significant at small a probability (0.05 or less) 
t Chi-square= 25.0264, P = 0.0001 *(Likelihood Ratio Test) 
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Table 14: Final logistic regression model for patients' current feeling 
about reinitiating drug therapy. Regression coefficients, standard error, 
and chi-square for the final set of variables belonging to European populationt. 
Variable Estimate Standard Chi-square p 
error 
Interce_I!_t -15.9527 858.6000 0.0003 0.9852 
Race 13.9950 858.6000 0.0003 0.9870 
Number of 0.1858 0.0586 10.0376 0.0015* 
physician 
visits for 
J>_roblems 
Patients' 0.1007 0.0704 2.0468 0.1525 
satisfaction 
towards 
health care 
provider 
Patients' 0.1478 0.0603 6.0043 0.0143 
satisfaction 
towards 
medications 
Number of 0.3276 0.2275 2.0735 0.1499 
medication 
additions 
* Significant at small a probability (0.05 or less) 
t Chi-square= 35.8091, P < 0.0001 *(Likelihood Ratio Test) 
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( 
( 
Table 15: Adjusted odds ratios and confidence intervals for demographic 
variables. 
Variable Adjusted odds Confidence 
ratio* interval _(95%1 
A_g_e 1.012 (0.994, 1.013) 
Education 1.284 (0.856, 1.926) 
level 
Em_p_lo_y_men t 0.997 (0.618, 1.608) 
Income 0.849 (0.571,1.262) 
Medical 2.190 (1.164,4.121) 
_p_~ment_!n!_e 
Race 3.499 (1.283,9.5371 
Gender 1.402 l_0.951,2.066) 
*Adjusted odds ratios calculated using Mantel-Haenszel procedure. 
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( Table 16: Adjusted odds ratios and confidence intervals for disease related 
variables. 
Variable Adjusted odds Confidence 
ratio* intervalJ95%l 
Physical health 0.967 (0.945-0.990) 
scale 
Number of 1.038 (0.441-2.445) 
hypertension 
related 
hos_I!_italizations 
Number of ER 1.030 (0.463-2.291) 
visits for blood 
_l!_ressure 
Number of 1.114 (1.033-1.203) 
physician visits 
for _l!_roblems 
Number of 0.997 (0.900-1.104) 
nurse/physician 
assistant/nurse 
_l!_ractitioner 
*Adjusted odds ratios calculated using Mantel-Haenszel procedure. 
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Table 17: Adjusted odds ratios and confidence intervals for psychological 
variables. 
Variable Adjusted odds ratio* Confidence 
interval _0)5%) 
Mental health scale 0.996 (0.973, 1.020) 
General health status 0.931 (0.696, 1.2431 
Patients' satisfaction 1.245 (1.113,1.391) 
towards health care 
_p_rovider 
Patients' satisfaction 0.818 (0.718,0.932) 
towards self-
mana_g_ement 
Patients' satisfaction 0.934 (0.807, 1.080) 
towards de_gree of control 
Patients' satisfaction 1.286 (1.162, 1.422) 
towards medication 
Patients' satisfaction 0.927 (0.838, 1.025) 
towards other services 
*Adjusted odds ratios calculated using Mantel-Haenszel procedure. 
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Table 18: Adjusted odds ratios and confidence intervals for medication 
related variables. 
Variable Adjusted odds ratio* Confidence 
interval (95%) 
Medication/medications 0.763 (0.456, 1.277) 
prescribed for the first 
time 
Number of dosage 1.346 (0.998, 1.815) 
chan_g_es 
Number of medication 2.770 (1.394,5.502) 
addition 
Number of medication 0.723 (0.483,1.084) 
deletions 
Number of medication 1.323 (0.825,2.121) 
switches 
*Adjusted odds ratios calculated using Mantel-Haenszel procedure. 
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( Table 19: Adjusted odds ratios and confidence intervals for the final set of variables in overall population. 
Variable Adjusted odds ratio* Confidence 
interval _0)5%1 
Race 2.628 (0.957,7.2191 
Number of physician 1.118 (1.027,1.218) 
visits for _p_roblems 
Patients' satisfaction 1.112 (1.007, 1.228) 
towards health care 
_l!_rovider 
Patients' satisfaction 1.141 (1.046, 1.244) 
towards medications 
Number of medication 1.746 (1.097,2.777) 
additions 
*Adjusted odds ratios calculated using Mantel-Haenszel procedure. 
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( Table 20: Adjusted odds ratios and confidence intervals for the final set of variables in North American population. 
Variable Adjusted odds ratio* Confidence 
intervalJ_95°/tl_ 
Race 2.305 (0.780,6.8081 
Number of physician 0.973 (0.854, 1.109) 
visits for _Qroblems 
Patients' satisfaction 1.157 (0.994, 1.346) 
towards health care 
_provider 
Patients' satisfaction 1.120 (0.976, 1.287) 
towards medications 
Number of medication 3.683 (1.313, 10.331) 
additions 
*Adjusted odds ratios calculated using Mantel-Haenszel procedure. 
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Table 21: Adjusted odds ratios and confidence intervals for the final set of 
variables in European population. 
Variable Adjusted odds ratio* Confidence 
interval _(95%1 
Race >999.999 (<0.001,999.999) 
Number of physician 1.204 (1.073, 1.351) 
visits for J!.roblems 
Patients' satisfaction 1.106 (0.963-1.270) 
towards health care 
_p_rovider 
Patients' satisfaction 1.159 (1.030, 1.305) 
towards medications 
Number of medication 1.388 (0.888,2.167) 
additions 
*Adjusted odds ratios calculated using Mantel-Haenszel procedure. 
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SAS PROGRAM ( 
58 
( libname prafulla 'h:\prafulla'; 
options nocenter; 
proc format; 
value yesno 
1= 'NO' 2= 'YES' ; 
value yesnorev 
1= 'YES I 2= 'NO'; 
value q12fmt 
l='POOR' 2='FAIR' 3='GOOD' 4='VG' S='EXC' ; 
value q39fmt 
l='NONE TIME' 2='LITTLE TIME' 3='SOME TIME' 
4='MOST TIME' S='GOOD BIT TIME' 6='ALL OF TIME'; 
value q56fmt 
l='WHITE' 2='BLACK' 3='HISPANIC' 4='ASIAN'; 
value q57fmt 
l='NEVER MAR' 2='MARRIED' 3='LIVE W/PART' 
4='SEPARATED' S='DIVORCED' 6='WIDOW(ER) '; 
value q60fmt 
l='ELEM SCHOOL' 2='SOME H.S. I 3='H.S . DEGREE' 
4='BUS/TECH SCH DEGREE' S='SOME COL' 6='COL DEGREE' 
7='SOME GRAD SCH' B='GRAD SCH DEGREE'; 
value q61fmt 
l='FULL-TIME' 2='PART - TIME' 3='UNEMPLOYED' 
4='HOMEMAKER' S='STUDENT' 6='RETIRED' ; 
value q62fmt 
1 = '<20K' 2='20K TO <30K' 3='30K TO <SOK' 
4='50K TO <75K' 5='75K TO <lOOK' 6='>=100K'; 
value q63fmt 
l='NOT REIMBURSED' 2='GOVT REIMBURSED' 3='WORK INSUR REIMB' 
4='SELF INSUR REIMB'; 
value q64fmt 
l='MALE' 2='FEMALE'; 
value races 
l='WHITE' 2= ' NONWHITE'; 
value marstats 
1 = I MAR I 2 = I NOT MAR I ; 
value educs 
1='< H.S. DEGREE' 2='>= H.S . DEGREE'; 
value employs 
l='FULL/PART' 2='UNEMP/HOMAK/STU/RET'; 
value incomes 
1='< 30K' 2='>= 30K'; 
value medpays 
l='NOT REIMBURSED' 2='REIMBURSED'; 
value medclass /*ADD THIS TO READBM7.SAS */ 
l='ACE INHIBITOR' 2='ACE+DIURETIC' 
3='AIIRA' 4='AIIRA+DIURETIC' 
S='BETA BLOCKER' 6='BB+DIURETIC' 
7='CCB' B='DIURETIC' 9='0THER'; 
value visfmt /* ADD THIS FMT TO READBM9 . SAS */ 
0='0' 1='1-2' 2='>2'; 
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( value q29fmt /* READBMll.SAS FORMATS */ l='NEV SMK' 2='QUITSMK >3YRS' 3='QUITSMK <=3YRS' 4='CUR SMK'; 
value smkstats 
l='NON/EX-SMK' 2='CUR SMK'; 
value countrys 
l='USA' 2 ='CANADA' 3='FRANCE' 4='GERMANY' 5='ITALY'; 
value stgfmt /* TINAT2 . SAS FMT */ 
l='PC' 2='C' 3='P' 4='A' 5='M'; 
value bplasts 
O='NO' l='YES'; 
value ergps 
/* READBM9B . SAS FMTS */ 
0= I 0 I l= I >=1 1 ; 
value medchgps 
1='0' 2='1-2' 3='>2'; 
/* CLINCOD.SAS FMTS */ 
value stggps 
l='PRE-ACTION' 2='POST-ACTION'; 
value hlth2fmt 
l='POOR/VAIR' 2='GOOD/VG/EXC'; 
value medclfmt 
l='DIURETIC GP' 2='AIIRA GP' 
3 = I OTHER GP I ; 
/* CLINCOD2 . SAS FMTS */ 
value difmt /* CLINCOD3.SAS FMTS */ 
O='NON-DIURETIC' l='DIURETIC'; 
value consider 
O='PC STG ONLY' l='C OR P STG'; 
DATA a; 
label survdt='SURVEY DATE= 6/1/97'; 
monsince=(survdt-datediag)/30.4; 
label monsince='NO. MONTHS SINCE lST DIAGNOSED'; 
vispermo=qlOa/monsince; 
label vispermo='# ROUTINE BP VIS PER MO SINCE DIAG'; 
if qq23a in(2,4,6,8) then prescldi=l; 
else if qq23a in(l,3,5,7,9) then prescldi=O; 
else if qq23a=. then prescldi=.; 
label prescldi='MEDPRESCl IS DIURETIC?'; 
consider=.; 
if stage=l then consider=O; 
if stage in(2,3) then consider=l; 
format consider consider.; 
data a; 
set prafulla . sfl2; 
keep iobs ql3a ql3b ql4a ql4b ql5a ql5b ql7a ql7b ql7c; 
proc sort out=a; 
by iobs; 
data b; 
set prafulla.bmsprt3; 
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I 
p r oc sort out =b; 
by iobs; 
data prafulla . bmspraf; 
merge a(in=inl) b(in=in2); 
by iobs; 
if in2; 
proc sort out=bmspraf ; 
by iobs; 
proc print data=bmspraf ; 
var q13a q21; 
run; 
libname Prafu lla 'h: \ Prafulla'; 
filename BMSPRTl 'h: \ Prafulla \ bmsprtl.txt'; 
options nocenter ls=72 ps=55 pageno=l; 
data prafulla.bms1128 ; 
infile BMSPRTl lrecl=429 n=l; 
input iobs 1-4 qllb 63-65 q2Bb 328-329 q2Bc 330-331 q2Bd 332-333 
q2 Be 334-335 ; 
proc sort out=Prafulla . bms1128; 
by iobs ; 
proc contents ; 
title 'CONTENTS OF BMS HTN PART 1 DATA FILE PRAFULLA.BMSPRTl 
(N=731) I; 
run; 
data a; 
set prafulla.sf12 ; 
keep iobs pcs12 mcs12; 
proc sort out =a ; 
by iobs ; 
data b; 
set prafulla.bmsfinal; 
proc sort out=b; 
by iobs ; 
data prafulla. bmsfin; 
merge a(in=inl) b(in=in2); 
by iobs; 
if in2; 
proc print data=prafulla.bmsfin ; 
var pcs12 mcs12; 
run; 
data a; 
set prafulla.bms1128; 
keep iobs qllb q28b q28c q28d q28e; 
proc sort out=a ; 
by iobs; 
data b; 
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set prafulla . bmspraf ; 
proc sort out=b ; 
by iobs; 
data prafulla.bmsfinal; 
merge a(in=inl) b(in=in2); 
by iobs; 
if in2; 
proc sort out=bmsfinal ; 
by iobs; 
run; 
proc freq data=a; 
table feeling*q56 feeling*q64 feeling*q56 feeling*q60 
feeling*q61 feeling*q62 feeling*q63 feeling*q60/ nopercent 
nocol; 
run ; 
data a; 
set prafulla.bmspraf; 
if q32 2 or q32 = 3 then feeling l; 
if q32 1 then feeling = O; 
if q32 4 or q32 = . then delete; 
if q56 1 then races = l; 
else races = 2· I 
if q60 = 1 or q60 2 or q60 = 3 then 
else educs = 2 i 
if q61 = 1 or q61 2 then employs 
else employs = 2· I 
if q62 = 1 or q62 2 then incomes 
else incomes = 2; 
if q63 = 1 then medpays = l; 
else medpays = 2; 
proc freq; 
educs 
1· I 
1 · I 
1 · I 
tables races q64 incomes educs employs medpays q64*races; 
proc logistic data=a descending ct; 
model feeling = q55 educs employs incomes medpays races q64 q64*races 
I printi lackfit CI; 
titlel 'LOGISTIC REGRESSION MODEL:DEP VAR IS FEELING'; 
title2 'INDEP VARS DEMOGRAPHIC CHARACTERISTI CS'; 
run; 
proc logistic data=a descending ct; 
model feeling = q55 educs employs incomes medpays races q64 marit/rl 
printi lackfit CI; 
run ; 
proc logistic data=a descending ct; 
model feeling = q55 educs employs incomes medpays races q64 q53/rl 
printi lackfit CI; 
run ; 
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data a; 
set prafulla.bmspraf; 
if qq23a 2 or qq23a 4 or qq23a 6 or qq23a 8 then medfirst = 1; 
if qq23a 1 or qq23a 3 or qq23a 5 or qq23a 7 or qq23a = 9 then 
medfirst 0; 
if qq24a 2 or qq24a 4 or qq24a 6 or qq24a 8 then medcurr = l; 
if qq24a 1 or qq24a 3 or qq24a 5 or qq24a 7 or qq24a = 9 then 
medcurr = O; 
proc logistic data=a descending ct; 
model feeling = medfirst medcurr q19 q20 q21 q22 I printi lackfit CI; 
titlel 'LOGISTIC REGRESSION MODEL:DEP VAR IS FEELING'; 
title2 'INDEP VARS MEDICATION RELATED'; 
run ; 
data a; 
set prafulla.bmspraf; 
proc logistic data=a descending ct; 
model feeling = medfirst q19 q20 q21 q22 /rl printi lackfit CI; 
run ; 
proc logistic data=a descending ct; 
model feeling = qSS educs employs incomes medpays races q64 I printi 
lackfit CI ; 
titlel 'LOGISTIC REGRESSION MODEL:DEP VAR IS FEELING'; 
title2 'INDEP VARS DEMOGRAPHIC CHARACTERISTICS'; 
run ; 
proc corr; 
var qSS educs employs incomes medpays races q64 feeling; 
proc logistic data=a descending ct; 
model feeling = qSS educs employs incomes medpays races q64 
qSS*employs q64*races /rl printi lackfit CI; 
titlel 'LOGISTIC REGRESSION MODEL:DEP VAR IS FEELING'; 
title2 'INDEP VARS DEMOGRAPHIC CHARACTERISTICS'; 
run ; 
proc logistic data=a descending ct; 
model feeling = q55 educs employs incomes medpays races q64 
qSS*employs /rl printi lackfit CI; 
run ; 
proc logistic data=a descending ct; 
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model feeling = q55 educs employs incomes medpays races q64 q64*races 
/rl printi lackfit CI; 
run ; 
proc logistic data=a descending ct; 
model feeling = q55 educs employs incomes medpays races q64/rl printi 
lackfit CI; 
run; 
proc logistic data=a descending ct; 
model feeling medpays races /rl printi lackfit CI; 
run ; 
proc logistic data=a descending ct; 
model feeling = q55 educs employs incomes medpays races q64 
races*medpays/rl printi lackfit CI; 
run ; 
proc logistic data=a descending ct; 
model feeling = q55 educs employs incomes medpays races q64 q64*races 
medpays*races /rl printi lackfit CI; 
run ; 
data a; 
set prafulla.bmsfinal; 
if q32 2 or q32 = 3 then feeling 
if q32 1 then feeling = 0; 
if q32 4 or q32 = then delete; 
if q56 1 then races = l· I 
else races = 2; 
if q60 = 1 or q60 2 or q60 = 3 then 
else educs = 2. I 
if q61 = 1 or q61 2 then employs 
else employs = 2; 
if q62 = 1 or q62 2 then incomes 
else incomes = 2; 
if q63 = 1 then medpays = l; 
else medpays = 2; 
if ql3a 3 or ql3a = 2 then moderate 
if ql3a 1 then moderate = O; 
if ql3b 3 or ql3b = 2 then climbing 
if ql3b 1 then climbing = O; 
proc logistic data=a descending ct; 
l ; 
educs l · I 
l· I 
l; 
l· I 
l · I 
model feeling = moderate climbing ql4a qBb q9b qlOb qllb 
lackfit CI; 
titlel 'LOGISTIC REGRESSION MODEL:DEP VAR IS FEEL ING '; 
title2 'INDEP VARS DISEASE RELATED VARIABLES'; 
r un ; 
data a; 
set prafulla.bmsfin; 
proc logistic data=a descending ct; 
/rl printi 
model feeling = pcsl2 qBb q9b qlOb qllb /rl printi lackfit CI; 
r u n ; 
p r o c logistic data=a descending ct; 
64 
model feeling 
CI; 
run ; 
pcs12 q8b q9b qlOb qllb q7a q7b /rl printi lackfit 
proc logistic data=a descending ct; 
model feeling = pcs12 qab q9b qlOb qllb pcs12*q10b /rl printi lackfit 
CI ; 
run ; 
data a; 
set prafulla.bmsfinal; 
proc logistic data=a descending ct; 
model feeling = q17a q17b q17c qlSa q12 q28a q28b q28c q28d / rl printi 
lackfit CI; 
run; 
data a; 
set prafulla . bmsfin; 
proc logistic data=a descending ct; 
model feeling = mcs12 q12 q28a q28b q28c q28d q28e /rl printi lackfit 
CI; 
run ; 
data a; 
set prafulla.bmsfin; 
proc logistic data=a descending ct; 
model feeling = mcs12 q12 q28a q28b q28c q28d q28e q28a*q28b q28b*q28d 
q28a*q28d /rl printi lackfit CI; 
run ; 
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HYPERTENSION STUDY 
PATIENT QUESTIONNAIRE 
Paragon Job Number 196- 181 
Research & Consulting Respondent ID Paoli Executive Green II, Suite 30 I 
43 Leopard Road City Code 
Paoli, PA 19301-1517 
(610) 889-7556 Quota group: 
PLEASE NOTE: ALL INTERVIEWER Male, 60 and Wldcr 1 
DIRECTIONS ARE IN CAPS AND ARE NOT TO Male, 61 and over 2 
BE READ TO RESPONDENTS. Female, 60 and under 3 
Female, 61 and ~ver 4 
INTRODUCTlON 
Mr ./Ms. ___ you may recall that we are cooducting ~·study aimed at improving the services and products which 
support pati~ts in their efforts to live with high blood pressure. To accomplish this, we'd like to know bow you feel 
about your high blood pressure now, and how interested you might be in some potential services and products. Please 
remember that your answers will be kept strictly confidential. No one, including your doctor, will ever see them. 
l. I'd like to start by focusing on the point when you were first diagnosed with high blood pressure. When did your 
doctor first tell you that you bad high blood pressure? Please give me the month and year. 
(RECORD "DON'T KNOWS" AS 0 I 0) I MONTWY'EAR. DIAGNOSED 
2. What was your blood pressure at that time? 
(RECORD "DON'T KNOWS" AS 0 I 0) 
I BLOOD PRESSURE AT flRST DIAGNOSIS 
3 . When your doctor first diagnosed you with high blood pressure, did be or she prescribe blood pressure medication for 
you during the same office visit? 
I: 
(IF RESPONDENT ANSWERS " NO" TO QUESTION 3, ASK QUESTIONS 4 AND 5. OTHERWISE, SKlP TO 
QUESTION 6.) 
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2 
4 . When did your doctor first prescribe medication for your high blood pressure? Just give me the month and ycac. 
(RECORD .. DON'T KNOWS" AS 0 I 0) 
MONTI I/YEAR FIRST PRESCRIBED BP MED 
5. What was your blood pressure at !hat time? 
(RECORD " DON'T KNOWS" AS 0 I 0) 
BLOOD PRESSURE AT FIRST PRESCRIP'TlON 
6. When did your doctor last chock your high blood pressure? 
(RECORD "DON'T KNOWS" AS 0 I 0) I MONTH/YEAR OF VISIT 
7. What was your blood pressure at !hat time? (LAST VISIT). 
(RECORD "DON'T KNOWS" AS 0 I 0) 
BLOOD PRESSURE AT LAST VISIT 
8. How many times, if ever, have you been hospitalized for any reason since you were first diagnosed with high blood 
pressure? ... (PAUSE TO RECORD ANSWER) ... How many times were you hospitaliz.cd for your high blood 
pressure? 
(RECORD " DON' T KNOWS" AS 999) 
#OF HOSPITALIZATIONS (TOTAL) 
I OF HYPERTENSION-RELATID HOSPITALIZATIONS 
9. How many times, if ever, have you made a routine visit to an emergency room for your high blood pressure since you 
were first diagnosed? Please DO NOT include any visits you may have made to the emergency room for a problem 
related to your blood prcssure ... (PAUSE) ... Now, how many visits have you made to an emergency room for problems 
related to your blood pressure since you were first diagnosed? 
(RECORD "DON'T KNOWS" AS 999) 
I OF ROUTINE ER VISITS FOR BLOOD PRESSURE 
r OF ER VISITS FOR BLOOD PRESSURE PROBLEMS 
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10. How many ROUTINE visits for your blood pressure have you made to a doctor since you were first 
diagnosed? ... (PAUSE) ... How many times have you visited a doctor foe PROBLEMS with your blood pressure? 
(RECORD UDON'T KNOWS"' AS 999) 
I OF ROUTINE PHYSICIAN VISITS 
I OF PHYSICIAN VISITS FOR PROBLEMS 
l l. How many ROUTINE visits for your blood pressure have you made to a nurse, physician's assistant. or nurse 
practitioner without seeing a doctor since you were first diagnoscd? ... (PAUSE) ... How many times have you visited a 
nurse, physician's assistant. oc nurse practitioner without seeing a doctor (or PROBLEMS with your blood 
pressure? 
(RECORD "DON'T KNOWS" AS 999) 
I OF ROUTINE WPAINP VISITS 
I OFWPAMP VISITS FOR PROBLEMS 
12-l&. Next. I'm going to hand you the questionnaire. On it. you will sec a series of questions that asks for your views about 
your health. Please answer every question by marking one box. If you arc WlSurc about how.to answer, please give 
the best answer you can. Please continue oo with each page until you see an instruction to return the questionnaire lo 
me contained in the box at the bottom of the page. 
(INTERVIEWER; OBSERVE RESPONDENT AS HFJSHE ANSWERS QUESTIONS 12-18, ENSURING THAT 
ONE BOX IS CHECKED FOR EVERY ANSWER.) 
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12. In gener>I, would you say your health is : 
Excellent Very good Good Fair Poor 
13. The following items nee about activities you might do during a typical day. Does your health now limit you in these 
activities? If so, how much? 
Yes, Limited A Y cs, Limited A No, Not Limited 
Lpt Little At All 
Moderate activities, such as moving a table, pushing a vacuum 
cleaner, bowling, or playing golf 
Climbing several flights of stairs 
14. During the past 4 weeks have you had any of the following problems with your work or other regular daily activities 
as a result of your physical health? 
YES NO 
l Accomplished less than you would like 
[Were limited in the kind of work or other activities 
15. During the past 4 ws:cl..--s have you had any of the following problems with your work or other regular daily activities 
as o result of nnv emotional problems (such as feeling depressed or anxious)? 
YES NO 
[Accomplished less than you would like 
l Didn'tdo work or other activities as carefully as usual 
II Please continue with the next page.. 
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16. · Duiing the post 4 weeks, how much did l2Jlin interfere with your nonnol work (including both work outside the home 
and housework)? 
Nototoll A little bit Moderately Quite a bit Excremcly 
17. These questions ore obout bow you feel and how things have been with you during the past 4 weeks. For each 
question, please give the one answer !hot comes closest to the woy you have 1Jecn feeling. How much of the time 
during the pnst 4 weeks -
All of the Most of A Good Bit Some of A Little of None of the 
Time the Time of the Time the Time the Time Time 
L.!i'.'ve you felt.calm nod peaceful? ~ ~ 71 --y ~ I 
V 11_d you have a lot of energy? 
L'Have you felt downhearted and blue? 
LI\ During the pgst 4 weeks how much of the time has your phvsical health or emotional problems interfered with your 
social nctivities (like visiting with friends. rdatives, etc.)? 
All of the Most of Some of A Little of None of the 
Time the Time the Time the Time Time 
s J_ s :.:( I 
Please stop here and hand the questionnaire back to the interviewer. 
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19. Since you were first prescribed medication for your high blood pressure, how many times has your doctor changed the 
dosage or strength of your high blood pressure medication? 
(RECORD " DON'T KNO WS" AS 999) I . OF DOSAGE CHANGES 
20. How many times has your doctor added a new medication to the ones you were already tlllcing for your high blood 
pressure? 
(RECORD "DON'T KNOWS" AS 999) 
\ • oF MEDICATION ADDmONs 
21. How many times bas your doctor had you stop taking a blood prcsslue medication without replacing it with a new 
medication? 
(RECORD "DON'T KNOWS" AS 999) I ·OF MEDICATION DEU:TlONS 
22. How mnny times has your doctor had you stop talcing a high blood pressure medication. but then replaced it with one 
or more new ones? 
(RECORD " DON'T KNOWS" AS 999) I • OF MEOICA 110N SWITCHES 
(HAND CARD Q.23 TO RESPONDENT.) 
23. Please tell me the name of the medication or medications that your doctor firsf prcsaibed for your high blood 
pressure. 
(ALLOW RESPONDENT TO EXAMINE LIST. PROBE FOR SPECIFIC NAMES AND SPELLINGS OF 
MEDICA T!ONS AND VERIFY AGAINST MED!CA T!ON LIST.) 
NAME OF MEDICATION FROM UST 
OTHER (Specify) 
(IF ANSWERS TO 20, 21 ANO 22 ARE ALL " O" , SKIP TO QUESTION 25.) 
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24. Please tell me the nrun; of the medicat_ion or medications that you are now taking for your !Ugh blood pressure. 
(PROBE FOR SPECIFIC NAMES AND SPELUNGS OF MEDICATIONS AND VERIFY AGAINST 
MEDICA TlON LIST. IF RESPONDENT CANNOT RECALL NAME OF MED!CA TION, ALLOW HIM/HER 
TO EXAMlNE LIST. RECO~ NUMBER CORRESPONDING TO MED!CA TION.) 
(RECORD "DIC' IF PATIENT HAS TAKEN OTHER MED!CA TION BlIT DOES NOT KNOW THE NAME.) 
I OF MEDICATION FROM UST 
·OTHER (Specify) 
25 -27. Next, I'm going to b:mdyou the questionnaire. On it, you w'.!l see a list of problems you.may or may not have had in 
the past month. For each. please indicate whethe.-you have had the problem, and if it is due to your blood pressure 
or your blood pressure medication in the column to the immediate right If you don't think that it is due to either,just 
leave those two columns blank. If you hnve had the problem, please also indicate how bothered you were by it, using 
the scale to the rar right 
(HAND QUESTIONNAIRE TO RESPONDENT, AND IlLUSTRATE THE PROCESS OF FIILING OUT COLUMN Q.25, 
Q.26, AND Q.27 ACCORDING TO DIRECTIONS IN INTERVIEWER MANUAL ENSURE THE RESPONDENT IS 
FILLING IT OUT CORRECTLY, AND PROBE FOR A COMPl..ElE UST, INCLUDING OlHER SYMPTOMS.) 
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25-27 . Please indicate whether you hove hod the problem in the PAST MONTH, ond whether it was due to your blood 
pressure. your blood pressure medication, or nei ther. Then. if you h:ive had lhe problem in the r AST MONTH 
please indicate how bothered you were by iL ' 
COLQ.ll COLQ.26 COL Q.27 
HAVt:N"T l<AVI: DUE TO OUE TO NOT AT MO DER-
PROBLEMS KAO KAO BLOOD MEDI- ALL SUCl<TLY Al"u.Y VD\Y EXT'RDo(£Ly 
PRO&l.EM PROO LEM PRESSUIU: CATION 8<1n<EJt.ED 8<1n<EJt.ED BOTHER.ED 80Tl<EIW> BOTHER.ED 
Dryness of mouth I 2 I 2 l 2 3 4 5 
General weakness I 2 I 2 l 2 3 4 5 
Confusion I 2 I 2 I 2 3 4 5 
Heartburn l 2 l 2 l 2 3 4 5 
Itching l 2 I 2 I 2 3 4 5 
Shortness of breath I 2 l 2 ~· 2 3 4 5 Unable to sleep, insomnia I 2 I 2 l 2 3 4 5 
Mood swings I 2 l 2 I 2 3 4 5 
Difficulty remembering things I 2 I " 2 l 2 3 4 5 
Blurry vision l 2 I 2 l 2 3 4 5 
Wheezing, difficulty breathing l 2 l 2 l 2 3 4 5 
Hives or swelling of body or l 2 I 2 l 2 3 4 5 facial areas 
Extreme thirst l .2 I 2 l 2 3 4 5 
Lethargy, no energy to do I 2 I 2 l 2 3 4 5 things 
Difficulty thinking I 2 l 2 l 2 3 4 5 
Diarrhea l 2 I 2 l 2 3 4 5 
Loss of taste l 2 l 2 l 2 3 4 5 
Slow heartbeat l 2 l 2 l 2 3 4 5 
N ightmares I 2 I 2 I 2 ·3 4 5 
Cloudy thinking I 2 l 2 l 2 3 4 5 
Hair loss l 2 I 2 l 2 3 4 5 
Double vision l 2 l 2 l 2 3 4 5 
Lightheadcdncss I 2 I 2 I 2 3 4 5 
Nausea I 2 I 2 I 2 3 4 5 
Constipation I 2 I 2 l 2 3 4 5 
Ropid heartbeat or palpitations I 2 I 2 I 2 3 4 5 
Numbness or tingling ofhonds l 2 l 2 I 2 3 4 5 
\I Please continue with the next page. 
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(HAND RESPONDENT CARD Q.28) 
28. Now, for the ne><t five questions, I'd like you to think for o moment aboul everything lhat has happened to you since 
you were ficst diagnosed with high blood pressure. On this card is a scale from 0 to I 0, where 0 means very 
dissatisfied and I 0 means very satisfied.. Please use the scale to tell me how satisfied you are with the following 
items. How satisfied are you with ... (READ EACH ITEM) 
Very 
dissatisfied 
Neither satisfied 
nor dissatisfied 
Very 
satisfied 
The assistance you receive from your health care 0 l 2 3 4 5 6 7 8 9 pro:.-ider in managing your high blood pressure? 
Your ability to help yourself in managing your ~ 3 5 6 7 8 9 high blood pressure? 0 l 2 4 
The degree to which your high blood pressure is 0 l 2 3 4 5 6 7 8 9 
controlled? 
The medications that are available for you to use 0 l 2 3 4 5 6 7 8 9 in managing your high blood pressure? 
The other services that are available for you to 0 l 2 3 4 5 6 7 8 9 
use in managing your high blood pressure? 
"(HAND RESPONDENT CARD Q.29) . 
29. Now I'd like to ask you a few questions about cigarette smoking. Which of the statements listed on this card best 
describes you and cigarette smoking? 
I NEVER SMOKED l 
I STOPPED SMOKING MORE THAN 2 
THREE YEARS AGO 
I STOPPED SMOKING WITHIN THE LAST 3 
THREE YEARS 
I SMOKE REGULARLY 4 
(IF ANSWER TO QUESTION 29 IS" l ", "2". OR "3". ASK QUESTION 30.) 
30. Do you live and/or work with smokers? 
\: 2 
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10 
10 
10 
10 
10 
. .:-
· t· 
Do you drink olcohol? About how mony drinks,~. :ind/or glasses of wine do you have in o week? 
(RECORD NUMBER. OF DRINKS PER. WEEK. IF RESPONDENT DOES NOT DRINK, ENTER. "O".) 
I • DRINKS PER WEEK 
(H/)ND RESPONDENT CARD Q.32.) 
32. Sometimes people find it difficult to take their mcdication(s) as directed liy !heir physician. " As d.irect.cd" means 
consistently tnking the amount of your mcdicntion(s) prescribed by your physician at the timc(s) prescribed by your 
physician. Please find the statement listed on this card that best describes the way you feel right now about taking 
your high blood pressure medications AS DIRECTED. ' 
NO, I DO NOT, AND IUGHT NOW I AM NOT CONSIDERING TAKING MY r' 
lllGH BLOOD PRESSURE MEDICATION AS DIRECTED . l 
. . 
NO, I DO NOT, BUT IUGHT NOW I AM CONSIDERING TAKING MY lllGH 2 BLOOD PRESSURE MEDICATION AS DIRECTED. 
NO, I DO NOT, BUT I AM PLANNING TO START TAKING MY lllGH BLOOD 3 PRESSURE MEDICATION AS DIRECTED WITHIN THE NEXT MONTH. 
YES, RIGHT NOW I CONSISTENTLY TAKE MY lllGH BLOOD PRESSURE 4 MEDICATION AS DIRECTED. 
(IF ANSWER TO Q.32 IS " II", ASK QUESTION 33.) 
33. How long have you been Wcing your high blood pressure medication as d.irect.cd? 
(READLTST) 
3 months or less I l 
J usl over 3 months to 6 moolhS 2 
Just over 6 months to 12 months 3 J 
More than 12 months 4 J 
34. In a moment. I'm going to hand the questionnaire to you to complete the next set of questions. The stotcrnenls in the 
ten hand column of the grid represent some thoughts and experiences that some people have when they are taking 
mcdication(s) as directed. Think obout your llloughls and experiences during the past month. For each situation, 
please circle the number under the slalcmcnl that best describes HOW OFTEN that thought has occurred to you in 
the past month. 
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34 . How often has each thought occurred to you in the p;is l month? 
Never Rarely Occnsionolly Often Very often 
I seek oul new inform01tion on the benefits of taking my l 2 3 4 5 medico1ion(s). 
! think oboul lhe benefits of toking my medicotion(s). l 2 3 4 5 
I coll my heollh care provider if I have questions about l 2 3 4 5 taking my medication(s). 
{ feel that my heolth care provider listens when I hove l 2 3 4 5 questions nbout my medication(s). 
R=tlnders from my family or friends help me 1 2 3 4 5 
remember to take my medication(s) ns directed. c 
Emotionnl suppott from others helps me take my 1 2 3 4 5 
medication(s) as direetcd. 
When I plan my day, { mnke sure to include tolcing mY 1 2 3 4 5 
medication(s). 
I use reminders to help me remember to take my l 2 3 4 5 
mediention(s) as directed. 
I use a pill orgnnizer or timer to help me take my 1 2 3 4 5 
medication(s) ns directed. 
When I am templed to skip a dose of my medicntion(s), 
I remind myself nbout the importance of stnying on l 2 3 4 5 
schedule. 
When it is difficult to toke my medication(s) ns directed. 1 2 3 4 5 { remind myself that others ore counting on me. 
I encourage myself to sticl< to my schedule for toking 1 2 3 4 5 
my medication(s). 
I use determinntion to help me sticl< to my regular l 2 3 4 5 
schedule for taking medicntion(s). 
I feel good nboul myself when I remember lo take my l 2 
mcdication(s) ns directed. 3 4 5 
1 feel more responsible when I nm taking my l 2 
medication(s) ns directed. 3 4 5 
I get upset with myself when I forget to take my l 2 3 4 5 
medication(s). 
Please continue with the next page 
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JS . On the ten hand side of the grid in Lhis question. you · 11 see some situations that might aITect whet.her you take yow-
mcdicotion(s) os directed to help lower your blood pressure. For coch situotion, pleose circle the number Wlder the 
stolement thot best describes HOW TEMPTED you would be to skip your mcdicotion(s) or take a dose which is 
different from lhe one prescribed. 
How tempted would you be lo skip your medication(s) or tnke a dose which is different from the one prescribed? 
When you feel good and think you don' t need iL 
When you arc womcd about the side effects. 
When you want to save on the cost of your 
medication(s). 
When you wonder why you need your niedication(s). 
When you feel unhappy. 
When you experience minor side effects. 
When you start to feel better. 
When your health care provider doesn't seem 
interested in whether you take your medication(s). 
When you have no energy. 
When your blood pressure is Wlder conlrol. 
When you doctor has not found the right drug for you. 
When your blood pressure is ll!2t under control. 
When another medication is added to your regimen. 
When you arc asked to come in for additional tests. 
When the dose of your medication is changed. 
When asked to come in for additional monitoring by 
your health care provider. 
When you have been drinking alcohol 
When you change your dieL 
When the general quality of your life is good. 
When you have reached your target wcighL 
When you :ue functioning well. 
When you think that controlling your blood pressure 
\\ithout medieation(s) is better. 
When a friend tells you that you don't need 
mcdication(s) to lower your blood pressure. 
Not at All 
Tempted 
1 
1 
1 
l 
1 
1 
' · l 
1 
1 
I 
1 
1 
1 
1 
1 
l 
l 
I 
1 
1 
l 
I 
I 
Slightly 
Tempted 
2 
2 
2 
~2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
Moderately 
Tempted 
J 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
Very 
Tempted 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
Please stop here and hand the questionnaire back to the interviewer 
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Extremely 
Tempted 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
( 
36. (continued) 
I wony that it's Wlhcalthy to control my high blood 
pressure with medication(s), instead of changes in diet. 
smoking and exercise. 
When I take my medication(s) ns directed. I feel more 
responsible. 
Talcing too mnny medication(s) may not be good for my 
health. 
Talcing my medication(s) ns directed may offset my 
Wlhealthy habits. 
Talcing medication(s) cortcctly may prevent high blood 
pressure symptoms from cccurring. 
I wony about the long tern\ side effects of taking 
medication(s). 
If [ take my medication(s) ns directed, I will live longer. 
' ifl take my medication(s) ns directed, they will 
eventually lose their effectiveness. 
If! take my medication(s) as directed, they will build up 
to hnnnful IC>'els in my body over time. 
If! take my medication(s) as directed, [can avoid a 
possible stroke or heart attack. 
I wony nbout taking my medication because I'm not sure 
that I really hnve high blood pressw-c. 
I feel thnt I am less likely to be a burden to others if I 
take my medication(s) as directed. 
Not 
Important 
1 
1 
1 
1 
1 
l 
1 
1 
l 
l 
l 
l 
Slightly 
lmportnnt 
2 
2 
~ 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
Moderately 
Important 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
Very 
Important 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
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Extremely 
Important 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
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